UDENAFIL


Synonyms	DA-8159 Udenafil Zydena
Status
Molecule Category	UNKNOWN
ATC	G04BE11
UNII	L5IB4XLY36


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	IYFNEFQTYQPVOC-UHFFFAOYSA-N
Smiles	CCCOc1ccc(S(=O)(=O)NCCC2CCCN2C)cc1-c1nc2c(CCC)nn(C)c2c(=O)[nH]1
InChI	InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C25H36N6O4S
Molecular Weight	516.67
AlogP	2.83
Hydrogen Bond Acceptor	8.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	11.0
Polar Surface Area	122.21
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	36.0

Bioactivity

Mechanism of Action	Action	Reference
Phosphodiesterase 5A inhibitor	INHIBITOR	PubMed


Protein: Phosphodiesterase 5A Description: cGMP-specific 3',5'-cyclic phosphodiesterase Organism : Homo sapiens O76074 ENSG00000138735

Related Entries

Cross References

Resources	Reference
ChEBI	135926
ChEMBL	CHEMBL2103849
DrugBank	DB06267
DrugCentral	4141
FDA SRS	L5IB4XLY36
Human Metabolome Database	HMDB0015628
PharmGKB	PA164776753
PubChem	135413547
SureChEMBL	SCHEMBL120993

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).